TNFSF18 and cancer: A second barrier to an effective antitumor immunity relates to the lack of expression of costimulatory molecules in cancer cells.17 To overcome this intrinsic tumor challenge, we armed Delta-24-RGD to express GITRL on the surface of infected cancer cells, where it will be able to engage with GITR molecules present on the immune cells.